ArticleEJNMMI physics2026
Monte Carlo microdosimetry of
Article in EJNMMI physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadionuclide therapy is an increasingly used treatment modality for patients with disseminated cancer diseases. Tumor-binding radiopharmaceuticals labelled with the alpha-particle emitter astatine-211 (
resultsBoth a single and a multiple thyroid follicle model designed for man, rat and mouse were used from previously published studies. Monte Carlo simulations and absorbed dose-calculations were performed for different distributions of 211At within the thyroid models. The mean specific energy, single-hit mean specific energy and single-hit specific energy distribution were calculated for follicle cell nuclei in models for each species.
conclusionThe overall agreement between AlfaMC and MCNPX results, and between AlfaMC and Geant4 results, was found to be within 5% and 2%, respectively. The intercomparison suggested an effective way for validation of microdosimetry results; of AlfaMC validation, a code designed with a focus on reducing the calculation time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.